Affiliation:
1. Cardiovascular Research Laboratory, Department of Medicine, University of Wisconsin Medical School, Madison, Wisconsin 53706
Abstract
Lidoflazine, a newly developed coronary vasodilator, greatly enhances the coronary vasodilating action of adenosine and ATP. Experiments were designed to study the combined coronary vasodilating effects of adenosine and lidoflazine and to quantify the enhancement of coronary vasodilation of adenosine and ATP by prior administration of lidoflazine. Results of the experiments showed that the combined coronary vasodilating effects of adenosine and lidoflazine can be classified as supra-additive. For 3 hours after the administration of lidoflazine there was a great intensification (20 to 150 times) of the vasodilating action of adenosine or ATP. An adenosine-sparing effect of lidoflazine in whole blood was also demonstrated, and the enhancement of adenosine action is in part related to this effect. It is suggested that lidoflazine may also produce a change in the sensitivity of the smooth muscle of the coronary vessels to the direct or indirect action of adenosine.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine,Physiology
Reference8 articles.
1. Die Wirkung eines Pyrimidopyrimidin-Derivates auf die Sauerstoffversorgung des Herzmuskels;BRETSCHNEIDEH H. J.;Arzneimittel-Forsch.,1959
2. Stimulation of the coronary collateral circulation by Lidoflazine (R7904);SCHAPER W. K.;Arch. Exptl. Pathol. Pharmakol.,1965
3. Cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator;SCHAPER W. K.;J. Pharmacol. Exptl. Therap.,1966
4. Kompetitive Hemmung der katalysierten Adenosindiffusion als Mechanismus der coronarerweiternden Wirkung eines Pyrimido-pyrimidin-Derivates
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献